Theratechnologies Inc - Company Profile
Powered by 
All the data and insights you need on Theratechnologies Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Theratechnologies Inc Strategy Report
- Understand Theratechnologies Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, CD-4 directed post-attachment HIV-1 inhibitor indicated for HIV type 1 infection in the US. Its pipeline products include Trogarzo IV slow push for HIV and Egrifta F8 for NASH HIV. The company is also developing TH 1902 for triple-negative breast cancer and TH1904 for ovarian cancer. It develops products based on peptide stabilization technology to increase target protein resistance to enzymatic degradation. Theratechnologies is headquartered in Montreal, Quebec, Canada.
Headquarters
Canada
Address
2015 Peel Street, 11th Floor, Montreal, Quebec, H3A1T8
Website
www.theratech.com
Telephone
1 514 3367800
No of Employees
89
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TH (TSE)
Revenue (2022)
$81.8M
2.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
49.3%
(2022 vs 2021)
Market Cap*
$60.3M
Net Profit Margin (2022)
XYZ
50.3%
(2022 vs 2021)
* As of and is in US$
Theratechnologies Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Egrifta- HIV-associated lipodystrophy | EGRIFTA |
| Egrifta SV- HIV-associated lipodystrophy | TROGARZO |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with Marathon to modify certain conditions and terms of its credit arrangement. |
| 2022 | Others | In April, the company terminated the agreement with TaiMed for Trogarzo in European Territory. |
| 2021 | Contracts/Agreements | In October, the company entered into an agreement with AIFA for the reimbursement of Trogarzo for eligible people aged 18 and older living with multi-drug resistant HIV-1. |
Competitor Comparison
| Key Parameters | Theratechnologies Inc | MacroGenics Inc | Inovio Pharmaceuticals Inc | BioClonetics Incorporated | AIM ImmunoTech Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | United States of America | United States of America | United States of America |
| City | Montreal | Rockville | Plymouth Meeting | Philadelphia | Ocala |
| State/Province | Quebec | Maryland | Pennsylvania | - | Florida |
| No. of Employees | 89 | 339 | 122 | 4 | 26 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dawn Svoronos | Chairman | Executive Board | 2013 | 69 |
| Paul Levesque | Chief Executive Officer; Director; President | Executive Board | 2020 | 59 |
| Philippe Dubuc | Chief Financial Officer; Senior Vice President | Senior Management | 2016 | 56 |
| Christian Marsolais, Ph.D. | Chief Medical Officer; Senior Vice President | Senior Management | 2007 | 60 |
| Andre Dupras | Vice President - Human Resources | Senior Management | 2021 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer